Monday, 19 October 2026European Markets

MYHOTELMATCH Stock Bullish Momentum With A 28% Rise In The Last 21 Sessions

Loading stream...

(vianews) - shares of myhotelmatch (cac 40: mhm.pa) rose by a staggering 28.21% in 21 sessions from €0.02 to €0.02 at 04:07 est on friday, after two consecutive sessions in a row of losses. cac 40 is rising 0.25% to €7,317.43, following the last session's upward trend.

myhotelmatch's last close was €0.02, 43.79% below its 52-week high of €0.03.

about myhotelmatch

myhotelmatch s.a. engages in the development and exploitation of an online hotel reservation platform based on artificial intelligence (ai). it operates as an online travel agency based on the principle of online dating. the company, through its platform, connect a traveler and hotels with online hotel services whose profiles match. the company is based in biot, france.

earnings per share

as for profitability, myhotelmatch has a trailing twelve months eps of €0.04.

pe ratio

myhotelmatch has a trailing twelve months price to earnings ratio of 0.45. meaning, the purchaser of the share is investing €0.45 for every euro of annual earnings.

more news about myhotelmatch (mhm.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Sovereign, Local and Open AI: Infrastructure and Applied Intelligence Scale Up While Frontier-Lab Safety Scrutiny Grows
AI is shifting from cloud-rented models toward locally run, owned and open intelligence. ASUS/NVIDIA RTX Spark laptops pair with Nous Research's Hermes and ComfyUI, and Microsoft pushes hybrid local/cloud Windows. Cisco, NVIDIA and Marvell build open high-bandwidth AI infrastructure, and Hesai supplies real-world data for physical AI. In finance and commerce, Intuit, Zeta, Parloa/TELUS Digital and Snipp embed agentic AI into trusted financial and customer workflows, while OpenAI's math breakthroughs, its security disclosures and an executive's departure from its safety role keep safety and governance scrutiny high.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,397 source documents archived
Query this data → isubstrate.com